Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560933 | 0.87 | NPC1 (0.47) | GALR3NR2F2NPC1RAB9APOLB | |
| SCHEMBL31490318 | 0.87 | NPC1 (0.47) | GALR3NR2F2NPC1RAB9APOLB | |
| SCHEMBL5758834 | 0.86 | ELANE (0.55) | GALR3NR2F2NPC1RAB9APOLB | |
| SCHEMBL5434834 | 0.84 | GALR3 (0.46) | GALR3NR2F2NPC1RAB9APOLB | |
| SCHEMBL4021451 | 0.80 | ELANE (0.56) | POLBELANECCR1ALDH1A1NOTUM | |
| SCHEMBL4024102 | 0.80 | CCR1 (0.45) | ELANECCR1NOTUMDDR1 | |
| SCHEMBL4025359 | 0.80 | ELANE (0.48) | POLBNPSR1ELANECCR1ALDH1A1 | |
| SCHEMBL4019562 | 0.79 | PPARG (0.53) | POLBELANEKDM4ECCR1ALDH1A1 | |
| SCHEMBL4022981 | 0.78 | MAPT (0.53) | NPC1RAB9APOLBELANECCR1 | |
| SCHEMBL11895652 | 0.77 | ELANE (0.47) | NPC1RAB9AELANEKDM4ECCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10092552-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170224706-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-1663974-B1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1663974-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026124-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | GALR3 3322/4885NR2F2 1881/4885NPC1 4704/4885 |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, SERPINE1 | GALR3 1258/4885NR2F2 3151/4885NPC1 3817/4885 |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | GALR3 3322/4885NR2F2 1881/4885NPC1 4704/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | GALR3 3322/4885NR2F2 1881/4885NPC1 4704/4885 |
| US-20170224706-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | GALR3 3322/4885NR2F2 1881/4885NPC1 4704/4885 |
| US-10092552-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | GALR3 3322/4885NR2F2 1881/4885NPC1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.